A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a novel HER2-targeting ADC bearing a potent anthracycline derivate as payload (T-PNU) in a hum...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Lucia, Menzel, Ulrike, Prummer, Michael, Müller, Philipp, Buchi, Mélanie, Kashyap, Abhishek, Haessler, Ulrike, Yermanos, Alexander, Gébleux, Rémy, Briendl, Manfred, Hell, Tamara, Wolter, Fabian I., Beerli, Roger R., Truxova, Iva, Radek, Špíšek, Vlajnic, Tatjana, Grawunder, Ulf, Reddy, Sai, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341578/
https://www.ncbi.nlm.nih.gov/pubmed/30665463
http://dx.doi.org/10.1186/s40425-018-0464-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341578/
https://www.ncbi.nlm.nih.gov/pubmed/30665463
http://dx.doi.org/10.1186/s40425-018-0464-1

Ejemplares similares